Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation.

ABSTRACT: Although autologous stem cell transplantation (auto-HCT) is the standard of care for patients with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL), there is still a significant proportion of patients that relapse after the procedure. This review contemplates different treatment strategies for patients with cHL that relapse or progress after auto-HCT. Allogeneic stem cell transplantation (allo-HCT) has, for many years, been the only curative option for this group of patients. Although the advent of haploidentical donors has allowed for the possibility to allograft almost all patients that are in need of it and to eventually improve historical results, allo-HCT is still associated with substantial morbidity and mortality. Brentuximab vedotin (BV) is an antibody drug conjugate th

SUBMITTER: Domingo-Domenech E 

PROVIDER: S-EPMC7290321 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature